Kroger's push toward lower everyday prices and private label will squeeze legacy food brands from both sides: pressure on wholesale prices and lost share. Its three-year plan targets about $5 billion in customer-value investment and $4 billion in annualized cost savings. Retailers control shelves and consumers; weaker brands, neglected in favor of buybacks and M&A, may surrender more of the profit pool. Kroger itself risks pain from price wars. x.com  x.com  x.com  x.com  x.com 

PepsiCo faces a death spiral as GLP-1 drugs shrink snack volumes while it raises prices. Per @wallstengine, citing Bloomberg, PepsiCo plans to lift prices on select chips, soda and dips by year-end or early 2027, months after cutting snack prices by up to 15% to revive demand. North American food revenue fell 2% last quarter on flat volumes. Less volume and higher prices together will destroy the snack companies. x.com 

General Mills looks like a good buy after a sharp selloff. @tsxman notes it trades at trough multiples, as Campbell's does, possibly dragged down by Conagra's CEO change, and argues that consumers keep buying its products every week. x.com 

McDonald's faces GLP-1 drugs, runaway inflation, shifting Gen Z preferences and terrible management execution, leaving it in its worst drawdown in 20 years outside of COVID. x.com 

Coca-Cola looks like a great funding short, since nothing makes it immune to the risks that battered its staples peers. GLP-1 drugs, store brands, new entrants and supply-chain inflation should hit it too, and non-sugar drinks only slow the U.S. decline, though international has held up better. About 2% revenue growth is thin support for 25x earnings while peers sit at 2008 valuations; it could fall to 15x unless the other staples rebound dramatically. x.com  x.com  x.com  x.com  x.com  x.com  x.com  … Show more

McDonald's lacks pricing power, leaving it exposed as food supply and prices look set to become a major issue in 2027. Fast-food chains are price takers on the supply side with products that carry little pricing power, and their downtrend roughly coincided with GLP-1 drugs going mainstream. Without GLP-1s, companies like McDonald's would be worth bidding up aggressively now. x.com  x.com 

McCormick's deal to roughly double its share count to buy Europe's slowest-growing food consumer packaged goods business looks like a poor move made after its compounder multiple had already disappeared. Volumes held up until 2022 before some mix of price elasticity and GLP-1 drugs hurt them, and management incentives tied to three-year cumulative net sales growth help explain chasing size. x.com  x.com  x.com 

Jack in the Box, Wendy's and Papa John's could all go bankrupt as fast-food prices outrun what consumers will pay. Customers are pushing back or finding comparable value at chains like Chili's. Freight costs from diesel and trucker shortages, plus rising food costs, will squeeze margins. Menus likely need to reset lower, which is hard while input costs climb, and GLP-1 drugs also hurt volumes. Some may be acquired instead, and a few could offer select opportunities as prices reset. x.com 

Novo Nordisk is priced as if its story were permanently broken, and it is not. GLP-1 competition, pricing pressure and weaker guidance are fair concerns, but it remains one of the most important healthcare companies in the world, in one of the biggest markets on earth. Along with ServiceNow, it is one of the two names most liked at current levels, and its drawdown looks interesting. x.com 

Novo Nordisk is one of the best opportunities in the market and a safe haven in an AI-driven market, crushed while its long-term growth story is rebuilt. It trades at 9x earnings with a 4.64% dividend yield, controls about 80% of the GLP-1 weight-loss pill market and plans to scale oral GLP-1 capacity 10x by 2030. Revenue growth is expected to return to double digits in 2027, and it has partnered with Anthropic on drug discovery. It would need a 110% rally to regain its 200-week average. x.com